Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Burden of adolescent and young adult lung cancer in South Asia: 1990−2023.

Rushabh Shah, Ruoyi Zhang, Nishwant Swami et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22596

e22596 Background: Lung cancer is the leading cause of cancer mortality worldwide. South Asia, the world’s most populous r...

Prostate cancer screening in Nigeria: Findings from a multi-city community-based PSA testing outreach.

Oluwaseyi Malumi, Precious Eze, George Ikenna Orjih et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13597

e13597 Background: Prostate cancer is the most frequently diagnosed cancer and the leading cause of malignancy-related mor...

Comparative efficacy and safety of neoadjuvant immunochemotherapy, chemoradiotherapy, and chemotherapy in resectable locally advanced esophageal squamous cell carcinoma: A network meta-analysis of randomized controlled trials.

Jiazhi Mi, Shijie Fang, Jialiang Feng et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16140

e16140 Background: Neoadjuvant chemoradiotherapy (NCRT) followed by surgery is currently the standard of care for resectab...

Coping strategies adopted by caregivers of pediatric oncology patients navigating the economic burden of treatment in a tertiary cancer care center: A qualitative thematic analysis.

J. Simran Bishnoi, Rajkumar Kottayasamy Seenivasagam, Krishna Priya Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22004

e22004 Background: Economic distress due to cost of cancer treatment is a significant challenge for patients and caregiver...

A risk stratification schema for patients with non–small cell lung cancer with multiple organ metastases.

Gabriela Esnaola, Mengru Wang, Benjamin Resio et al. Jun 01, 2026 pp. 11138-11138 10.1200/jco.2026.44.16_suppl.11138

11138 Background: The majority of patients with non-small cell lung cancer (NSCLC) will have multiple organ sites of metas...

A clinical prediction score to identify symptomatic patients at high risk for colorectal cancer in South Africa.

Yoanna S. Pumpalova, Shakeel Kader, Thembeka Mngadi et al. Jun 01, 2026 pp. 1606-1606 10.1200/jco.2026.44.16_suppl.1606

1606 Background: Colorectal cancer (CRC) is the third most diagnosed cancer globally with a rising incidence across sub-Sa...

A phase 1 study of CT-01, a dual molecular glue degrader of GSPT1 and NEK7, as monotherapy and in combination with everolimus in patients with hepatocellular carcinoma.

Paweł Dobrzański, Andrew Saunders, Krzysztofa Odrzywol et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15108

e15108 Background: Targeted protein degradation (TPD) using molecular glues enables pharmacological modulation of previous...

Post-neoadjuvant Prognostic Nutritional Index as a predictor of pathological response and survival in locally advanced rectal cancer.

Marytere Herrera, Jairo Rubio, Consuelo Diaz et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15632

e15632 Background: The response to neoadjuvant therapy in locally advanced rectal cancer (LARC) may be influenced by tumor...

EA1181: Accuracy of pre-surgery MRI to predict pathologic complete response after taxane, trastuzumab, and pertuzumab (THP) in HER2-positive breast cancer.

Nadine M. Tung, Fengmin Zhao, Savannah C. Partridge et al. Jun 01, 2026 pp. 603-603 10.1200/jco.2026.44.16_suppl.603

603 Background: Accurate prediction of pathologic complete response (pCR) after preoperative therapy for HER2-positive (HE...

Use of immune checkpoint inhibitors in soft tissue sarcoma: A meta-analysis.

Stephanie Niforatos, Alanna Siegenthaler, Deevyashali Parekh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23560

e23560 Background: Soft tissue sarcomas (STS) have historically been treated with surgery, radiation, or chemotherapy. Rec...

Non-invasive strategy for gastric cancer detection: Integration of cell-free DNA fragmentomics and protein biomarkers.

Lian Lian, Yueqing Huang, Xuefei Xu et al. Jun 01, 2026 pp. 4071-4071 10.1200/jco.2026.44.16_suppl.4071

4071 Background: Gastric cancer (GC) ranks the fifth most common cancer worldwide. Although gastroscopy is widely acknowle...

Tumor mutational burden by smoking status in small cell lung cancer: Insights from a limited cohort.

Thomas Greco, Tahreem Malik, Joseph Maslak Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20122

e20122 Background: Tumor mutational burden (TMB) is a potential biomarker in small cell lung cancer (SCLC) and is often in...

Coordinated care interventions and time to treatment initiation in a public health system in Brazil.

Bianca Tanoue, Priscila Ardanaz, Andressa de Souza Barbosa Lima Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13513

e13513 Background: Delays in cancer treatment initiation are associated with increased morbidity and mortality. In Brazil,...

Projected burden of lung cancer and tobacco usage among older adults ≥ 65 in the United States: A CDC WONDER forecasting analysis, 1999–2035.

Areesha Nawaz, Fareed Baksh, Fnu Hafeezullah et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20083

e20083 Background: Lung cancer and tobacco use are closely linked, with smoking responsible for most cases. Evaluating lon...

Efficacy and safety of immune checkpoint inhibitors after platinum-based therapy for refractory or recurrent malignant pleural mesothelioma: A systematic review and meta-analysis.

Filipe Luis Vasconcelos Visani, Rebeca Ferreira De Souza, Lorrany Larisse Costa Rodrigues et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20064

e20064 Background: Malignant pleural mesothelioma (MPM) remains highly aggressive. While immune checkpoint inhibitors (ICI...

Early symptom signals preceding end-of-life decline in outpatient palliative oncology.

Flavia Santos Dumont Sorice, Sarah Ananda Gomes, Graziella Eugenio Tocafundo et al. Jun 01, 2026 pp. 12053-12053 10.1200/jco.2026.44.16_suppl.12053

12053 Background: Timely recognition of clinical decline is challenging in palliative oncology. Symptom trajectories that...

Closing the distance and the Specialist Nursing Optimal Placement Tool (SN-OPT): Strategic placement of specialist cancer nurses to achieve resource and geographic equity in Australia.

Rebecca Johnson, Georgina V. Long, Alexander M. Menzies et al. Jun 01, 2026 pp. 11082-11082 10.1200/jco.2026.44.16_suppl.11082

11082 Background: Cancer workforce planning that enables effective specialist nurse placement is critical for delivering h...

Stage-dependent divergence of immune prognostic signatures in non–small cell lung cancer.

Praveen Thapa, Trilok Shrivastava, Ashish Nepal et al. Jun 01, 2026 pp. 8066-8066 10.1200/jco.2026.44.16_suppl.8066

8066 Background: Tumor mutational burden (TMB) and immune activation are widely studied biomarkers in non–small cell lung...

mRNA-based profile to predict platin sensitivity in NSCLC assessed by Nanostring: A translational analysis of the ETOP/EORTC SPLENDOUR trial.

Beatrice Hahn, Urania Dafni, Jan Nart et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20555

e20555 Background: Platinum-based chemotherapy is a standard treatment for non-small cell lung cancer (NSCLC), yet clinica...

Use of multi-omics biomarkers to predict benefit from immune checkpoint inhibitors in biliary tract cancers: A systematic review and meta-analysis.

Neel Parikh, Sannidhya Singh, Suchita Mylavarapu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14587

e14587 Background: Predictive biomarkers for immune checkpoint inhibitors (ICIs) in biliary tract cancers (BTC) are urgent...

Correlation of PD-L1 expression with tertiary lymphoid structure maturity and immune cell spatial distribution in colorectal cancer.

Linhai Li, Yiming Ouyang, Yuejin Li et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15582

e15582 Background: PD-L1 expression is a key biomarker for predicting immune checkpoint inhibitor (ICI) efficacy but shows...

Indocyanine green–guided lymphadenectomy in gastrectomy for gastric cancer: A systematic review and meta-analysis.

Alyaa Ahmed Ibrahim, Fatma A. Rikabe, Abdelrhman H. Mohamed et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16098

e16098 Background: Indocyanine green (ICG) near-infrared fluorescence is increasingly used to guide lymphadenectomy during...

Efficacy and safety of deulorlatinib (TGRX-326) in patients with locally advanced or metastatic ALK+ non–small cell lung cancer: A multicenter, open-label, pivotal phase 2 trial.

Yunpeng Yang, Zhehai Wang, Yanqiu Zhao et al. Jun 01, 2026 pp. 8638-8638 10.1200/jco.2026.44.16_suppl.8638

8638 Background: Treatment options are limited for anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (...

Efficacy and safety analysis of hepatic arterial infusion chemotherapy plus PD-1/PD-L1 antibodies combined with donafenib or bevacizumab in patients with unresectable hepatocellular carcinoma.

Jinbin Chen, Wei Peng, Yaojun Zhang Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16155

e16155 Background: In unresectable hepatocellular carcinoma (uHCC), it is unknown whether donafenib plus hepatic arterial...

A prospective, single-arm, exploratory study on the efficacy and safety of romiplostim N01 for cancer treatment–induced thrombocytopenia in patients with gastrointestinal cancers.

Ying Yan, Gang Wang, Huijun Xu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16346

e16346 Background: Cancer Treatment-Induced Thrombocytopenia (CTIT) is a common complication in patients with gastrointest...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page